Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer

References

• Liboiron BD , Mayer LD. Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther Deliv 2014;5:149–71.
   PubMedGoogle Scholar
• Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9:3–13.
   PubMed Web of Science ®Google Scholar
• Stresing V , Daubine F , Benzaid I , et al . Bisphosphonates in cancer therapy. Cancer Lett 2007;257:16–35.
   PubMed Web of Science ®Google Scholar
• Ottewell PD , Lefley DV , Cross SS , et al . Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010;126:522–32.
   PubMed Web of Science ®Google Scholar
• Girardi M , Oppenheim DE , Steele CR , et al . Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294:605–9.
   PubMed Web of Science ®Google Scholar
• Hayday AC. γδ-cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975–1026.
   PubMed Web of Science ®Google Scholar
• Mattarollo SR , Kenna T , Nieda M , Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 2007;56:1285–97.
   PubMed Web of Science ®Google Scholar
• Coleman R , Gnant M , Morgan G , Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059–67.
   PubMed Web of Science ®Google Scholar
• Gnant M , Mlineritsch B , Schippinger W , et al . Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679–91.
   PubMed Web of Science ®Google Scholar
• Coleman R , Powles T , Paterson A , et al . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386:1353–61.
   PubMed Web of Science ®Google Scholar
• Shmeeda H , Amitay Y , Gorin J , et al . Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release 2010;146:76–83.
   PubMed Web of Science ®Google Scholar
• Shmeeda H , Amitay Y , Tzemach D , et al . Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J Control Release 2013;167:265–75.
   PubMed Web of Science ®Google Scholar
• Parente-Pereira AC , Shmeeda H , Whilding LM , et al . Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid. J Immunol 2014;193:5557–66.
   PubMed Web of Science ®Google Scholar
• Silverman L , Barenholz Y . In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site. Nanomedicine 2015;11:1841–50.
   PubMed Web of Science ®Google Scholar
• Gabizon A , Amitay Y , Tzemach D , et al . Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J Control Release 2012;160:245–53.
   PubMed Web of Science ®Google Scholar
• Bandak S , Ramu A , Barenholz Y , Gabizon A. Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Pharm Res 1999;16:841–6.
   PubMed Web of Science ®Google Scholar
• Chan FK , Moriwaki K , De Rosa MJ. Detection of necrosis by release of lactate dehydrogenase activity. Methods Mol Biol 2013;979:65–70.
   PubMedGoogle Scholar
• Gabizon A , Horowitz AT , Goren D , et al . In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003;9:6551–9.
   PubMed Web of Science ®Google Scholar
• Kohro T , Tanaka T , Murakami T , et al . A comparison of differences in the gene expression profiles of phorbol 12-myristate 13-acetate differentiated THP-1 cells and human monocyte-derived macrophage. J Atheroscler Thromb 2004;11:88–97.
   PubMedGoogle Scholar
• Gabizon AA , Tzemach D , Horowitz AT , et al . Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 2006;12:1913–20.
   PubMed Web of Science ®Google Scholar
• Marra M , Salzano G , Leonetti C , et al . Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011;7:955–64.
   PubMed Web of Science ®Google Scholar
• Gutman D , Epstein-Barash H , Tsuriel M , Golomb G . Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth. Adv Exp Med Biol 2012;733:165–79.
   PubMed Web of Science ®Google Scholar
• Gutman D , Golomb G. Liposomal alendronate for the treatment of restenosis. J Control Release 2012;161:619–27.
   PubMed Web of Science ®Google Scholar
• Thamake SI , Raut SL , Gryczynski Z , et al . Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 2012;33:7164–73.
   PubMed Web of Science ®Google Scholar
• Bonzi G , Salmaso S , Scomparin A , et al . Novel pullulan bioconjugate for selective breast cancer bone metastases treatment. Bioconjug Chem 2015;26:489–501.
   PubMed Web of Science ®Google Scholar
• Haran G , Cohen R , Bar LK , Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201–15.
   PubMed Web of Science ®Google Scholar
• Clezardin P , Ebetino FH , Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971–4.
   PubMed Web of Science ®Google Scholar
• Ottewell PD , Brown HK , Jones M , et al . Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat 2012;133:523–36.
   PubMed Web of Science ®Google Scholar
• Schilt Y , Berman T , Wei X , et al . Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs. Biochim Biophys Acta 2016;1860:108–19.
   PubMed Web of Science ®Google Scholar
• Maeda H , Nakamura H , Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013;65:71–9.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K , Motegi K , Iwakura Y , Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 2000;130:1646–54.
   PubMed Web of Science ®Google Scholar
• Norton JT , Hayashi T , Crain B , et al . Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1. J Immunol 2012;188:2977–80.
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 2014;61:163–73.
   PubMed Web of Science ®Google Scholar
• Szebeni J , Muggia F , Gabizon A , Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63:1020–30.
   PubMed Web of Science ®Google Scholar
• Rogers TL , Wind N , Hughes R , et al . Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr) 2013;36:505–14.
   PubMed Web of Science ®Google Scholar
• Sabnani MK , Rajan R , Rowland B , et al . Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine 2015;11:259–62.
   PubMed Web of Science ®Google Scholar
• Rajan R , Sabnani MK , Wood LM et al. Pegylated liposomal alendronate: The impact of the drug cargo on carrier-induced immune modulation. In AACR Annual Meeting 2016; Abstract # 4008.
   Google Scholar
• Benzaid I , Monkkonen H , Stresing V , et al . High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vγ9Vδ2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011;71:4562–72.
   PubMed Web of Science ®Google Scholar
• Clezardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011;48:71–9.
   PubMed Web of Science ®Google Scholar
• Clezardin P. Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med Chem 2012;12:102–13.
   PubMed Web of Science ®Google Scholar
• Clezardin P. Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep 2013;2:267.
   PubMedGoogle Scholar
• Gabizon AA , Shmeeda H , Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006;16:175–83.
   PubMed Web of Science ®Google Scholar